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Objectives: Gemeinsame Bundesausschuss (G-BA) states that it assesses addi-
tional benefit strictly on clinical grounds, but it also requires that manufacturers 
submit drug and comparator costs. This raises the possibility that G-BA’s assessment 
might be influenced by price, possibly to provide leverage during subsequent price 
negotiations. This research tests the hypothesis that high cost drugs (relative to 
the comparator) are more likely to receive poor benefit assessments. MethOds: 
The following variables were collected from the Federal Gazette publication or the 
“Beschluss” document: additional benefit assessment, annual cost per patient of 
drug and comparator, and estimated target population. The Scottish Medicines 
Consortium (SMC) clinical rationale for the same drugs and indications were col-
lected to control for clinical efficacy. After excluding orphan drugs, reviews using 
best supportive care comparators, and reviews without SMC reviews, 58 reviews 
remained for analysis. G-BA’s additional benefit assessments were ranked from 
least benefit to most. The influence of drug cost relative to the comparator on the 
G-BA assessment was estimated via an ordered logit model. The model also included 
controls for the (log) size of the target population and clinical efficacy (SMC’s clinical 
assessment). Results: An increase in the cost difference between the drug and the 
comparator is estimated to result in a modest, statistically significant increase in the 
odds of receiving an additional benefit assessment greater than a “no additional 
benefit” assessment. cOnclusiOns: Our results are inconsistent with the alterna-
tive hypothesis that G-BA is strategically discounting its assessment of relatively 
high cost drugs. The positive estimated relationship is consistent with manufactur-
ers’ setting higher prices for more beneficial drugs (The data available provide no 
way to statistically account for this plausible source of endogeneity). Our results 
provide no support for rejecting the null hypothesis that G-BA assesses added ben-
efit independently of drug cost.
PHP244
DeveloPment of Hta in turkey
Tuna E.1, Tatar M.2, Ergin G.1, Senturk A.1, Atikeler K.2
1Polar Polar Health Economics & Policy, Ankara, Turkey, 2Hacettepe University, Ankara, Turkey
Objectives: The aim of this study was to assess the development of HTA in 
Turkey. MethOds: In this regard, organization structures of the Ministry of Health 
(MoH) and Social Security Institution (SSI) and presentations of first HTA meet-
ing held in April 2014 have been analyzed. Results: There are three main HTA 
agencies in Turkey. One is under the payer institution called SSI. The HTA com-
mittee of SSI assesses all the new health technologies to define whether they will 
be reimbursed or not. In other words, this committee is the major decisive HTA 
committee. Other two HTA committees are under the MoH. One of these is under 
the General Directorate of Pharmaceuticals and Medical Devices. This committee 
assesses certain drugs which are specifically asked to be evaluated by the SSI, MoH 
or other Ministries. One of the projects completed by this committee is the evalua-
tion of top 100 selling drugs according to the effect of price, regulation, market and 
qualitative characteristics of drugs. The second committee of the MoH is under 
the General Directorate of Health Research. This committee assesses more general 
issues like obesity, KOAH etc., instead of certain health technologies and publishes 
national reports. One of the reports published by this committee was the impor-
tance of obesity surgery in the treatment of obesity. In addition to all these three 
committees, HTA studies also being carried out by a MoH hospital called Ankara 
Numune Training and Research Hospital (ANHTA). They have been working on hos-
pital based HTA. cOnclusiOns: Despite valuable studies being conducted as stated 
above, HTA is still in its infancy in Turkey and compared to other EU countries like 
Germany, UK etc. there is not an autonomous HTA agency. There are more than one 
committee, working on different aspects of health technology assessment under 
the supervision of government.
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bAckgROund: Defining health technology assessment priorities has been a chal-
lenge for the Department of Science and Technology who adopted a prioritiza-
tion criteria strategy (epidemiologic relevance, services/policy relevance, state of 
the art, operational feasibility and social demand) for demands from MoH tech-
nical areas. However, evaluation demands do not always correspond to health 
needs. Objectives: To analyze the relationship between projects financed from 2003 
to 2013 and disease burdens in Brazil. MethOds: Systematization of the summaries 
from financed projects through searches in the information from www.saude.gov.br/
rebrats and http://pesquisasaude.saude.gov.br/bdgdecit/ and categorization according 
to the twenty sub-groups of diseases and injuries of disease burden (Dalys) research 
in Brazil (SHARMM ET al, 1998). Results: 284 HTA projects financed between 2003 
and 2013. Of these, 24% (68/284) apply to the twenty main causes of loss of life years 
by premature death or incapacitation (Dalys, 1998). The first three largest are equal 
to 15% – diabetes, coronary ischemia, acute myocardial infarction, angina, cerebral 
infarction and stroke– corresponded to 13% of the (37/284) projects. cOnclusiOns: 
The percentage found allows for the questioning of the prioritization starting point 
where the criteria are applied to subjects selected due to external influence and 
pressure from the market and not necessarily based on the needs impacting the 
population’s health. Uniting the two dimensions while also taking into account the 
strategic innovations in order to prioritize and finance assessment will be important 
for health systems sustainability.
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Objectives: In a new regulation the Federal Joint Committee (G-BA) can pass 
directives for testing examination and treatment methods with not yet suffi-
ciently proven benefit, but which show potential as essential treatment alter-
natives (§137e SGB V). The objective of the present study was to compare the 
requirements for a successful application with the existing AMNOG (Law on the 
Reorganization of the Pharmaceutical Market) HTA requirements in Germany. 
The applicants must submit valid data on the potential of the method in ques-
tion, among other requirements. In one of the first applications in Germany, 
done by the authors, we see a lot of parallels with the HTA process for drugs but 
also a lot of uncertainties. MethOds: We compared the requirements of the 
IQWIG Methodology paper 4.2 and the G-BA rules of procedure for the early ben-
efit assessment for medical drugs (§35a SGB V) with the new potential analysis 
for examination and treatment methods. This analysis was made for different 
criteria’s like study and endpoint design, certainty of results of the studies and 
others. We used our business case as template to extract the key-learning’s 
and identify the pitfalls in the new process. Results: The new legislation will 
have a strong impact on the study design and evidence to show the potential 
of new examination and treatment methods as essential treatment alterna-
tives. A lot of evaluation criteria’s came from the drug assessments but are 
hardly applicable to proof the potential of new examination and treatment 
methods. cOnclusiOns: The legislation uses parts of classic HTA assessment 
on medical drugs to evaluate the potential of new examination and treatment 
methods. In most cases this is not possible and will decrease the level of evi-
dence of available clinical data for new examination and treatment methods 
due to grey zones and loopholes in the legislation.
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Objectives: This study aims to assess the existence of a correlation between 
the applicability of end-of-life treatment criteria and the likelihood of NICE 
requiring a Patient Access Scheme (PAS) to recommend the treatment for 
funding. MethOds: A review of all patient access schemes in existence as 
of March 2014 for NICE-recommended drugs was conducted to assess how 
many of those were for medicines which met the end-of-life treatment criteria 
and whether the supplementary criteria for end-of-life treatments had any 
bearing on the final NICE recommendation. Results: In total 42 PAS were 
identified. Of those, end-of-life treatment criteria were met and had bearing 
on the final NICE guidance in 7 cases (16.7%). End-of-life treatment criteria 
were considered but were not met in full in the case of 3 NICE reviews (in one 
of the three NICE considered that end-of-life criteria were not met in another 
review, even though the manufacturer had not applied for those criteria to 
be considered in the present review). End-of-life treatment criteria were also 
considered for one additional review where they were a focal point of the manu-
facturer appeal against the NICE guidance. In one additional case, end-of-life 
criteria were applied for but had no bearing on the final NICE guidance as the 
cost-effectiveness threshold was met without the application of special con-
siderations. cOnclusiOns: Given the high cost of drugs meeting end-of-life 
criteria (most of which are for oncology indications), as expected, many of them 
are subject to a PAS in the UK. However, the opposite correlation does not hold 
true - i.e., the requirement for a PAS in the UK is not restricted to end-of-life 
treatments.
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Objectives: At market entry, there usually is uncertainty regarding a new medi-
cine’s benefit-risk profile. Therefore, regulatory authorities may request additional 
pharmacovigilance (PhV) activities. Regulatory Authorities can request a Post-
Authorisation Safety Study (PASS) such as a registry, database study, survey, or 
clinical trial to reduce the uncertainty regarding certain safety risks. We aimed to 
assess the costs and effects of PASS for centrally approved new active substances 
(NAS) in Europe in 2007. MethOds: We compared two scenarios for all NAS (n= 47): 
(1) Full regulation: routine PhV activities (spontaneous adverse drug reaction (ADR) 
reporting) with additional PASSs for some NAS; (2) Limited regulation: only routine 
PhV activities. For a follow-up period of six years after marketing we assessed the 
safety-related labeling changes for NAS and identified the source of these changes 
(PASS, spontaneous ADR reporting or other). Data on labeling changes was extracted 
from the European Medicines Agency’s website. A survey among pharmaceutical 
companies was used to estimate the costs of all requested PASSs. Results: For 
23 of the 47 NAS, at least one PASS (33 PASS in total) was requested in 2007. After 
six years, on average 8.1 safety-related labeling changes were identified per NAS. 
Requested PASS were the source of ~4% of all cases of new safety information identi-
fied. The total estimated costs of the 33 requested PASS were between € 50 and € 150 
million. cOnclusiOns: For the 2007 cohort of NAS approved in Europe, the total 
costs of all requested PASS were substantial and yet these PASS contributed to the 
identification of only 4% of all new safety information identified post-marketing 
for NAS. However, PASS primarily aim to reduce uncertainty regarding safety risks 
and the (societal) value of this uncertainty reduction might not fully be captured 
by assessing health effects alone.
